STM publisher Elsevier, Netherlands, previewed the second generation of Inteleos at the SLA Division of Pharmaceutical & Health Technology (DPHT) spring meeting in St. Petersburg, Florida. A redesigned interface and the addition of US approved and tentatively approved generic drugs - seamlessly linked to the branded drug - gives business intelligence professionals unparalleled breadth and depth of content.
Other enhancements to Inteleos include expanded drug records with detailed development timeline overviews, drug properties, ongoing trials, competitor profiles and related news. The new Competitor Profile highlights products with the same mechanism of action or drug class in a simple interactive grid giving users a snapshot of the competitive landscape. Graphical timelines track progress through development to product launch, including actual and company predicted dates, so users can visualise the path to approval.
Building on the already heralded design, the new interface focuses on improved usability. The reorganisation of the search fields and addition of Boolean operators gives users the flexibility to conduct quick or complex searches. Combined with the expansive filter options, Inteleos makes it easier to pinpoint data most relevant to a user's needs.
